clinical trial · NCT07294261
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Sun Yat-sen University·phase2·not yet recruiting·n = 69
Local Advanced or Metastatic NSCLCGarsorasib, Benmelstobart, AnlotinibBenmelstobart, AnlotinibGarsorasib, Cetuximab Beta Injection
brief summary
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
started
Dec 23, 2025
primary completion
Oct 30, 2028
completion
Dec 30, 2028
last updated
Dec 19, 2025
official title
A Multicenter, Prospective Clinical Study Evaluating Goselasib Combination Therapy for First-Line Treatment of KRAS G12C Locally Advanced or Metastatic Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol